Exploratory Study of Xolair (Omalizumab)to Improve Outcomes in Patients With COPD and Elevated IgE Levels, and Positive RAST or Skin Prick Tests.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 20 Jul 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Feb 2009 New trial record